The programme is being implemented in collaboration with Grow Well Foundation and is expected to expand in a phased manner
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
India continues to face a major maternal nutrition challenge, with nearly 60% of women affected by anaemia and more than 70% experiencing calcium deficiency
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Subscribe To Our Newsletter & Stay Updated
